Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia

M. Hussain Habil, H. Gondoyoewono, H. R. Chaudhry, U. Samanwongthai, Abdul Hamid Abdul Rahman, I. T. Hashmi, R. Budiman, A. G. Knowles, R. Buenaventura

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: The objective of this study was to assess the effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients in an outpatient setting. Methods: This was an open-label, prospective, observational study involving 339 patients from Indonesia, Pakistan, Malaysia, Thailand, and Singapore. Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression Severity scale (CGI-S), and safety parameters were assessed. Results: 62% of patients responded to olanzapine treatment, defined a priori as a reduction in BPRS of> 40% from baseline. Following the 8-week treatment period, the BPRS total, BPRS positive, BPRS negative, and CGI-S scores decreased by 18.7 (95% CI: 17.4, 20.2), 6.1 (5.6, 6.6), 2.9 (2.6, 3.2), and 1.5 points (median 1.0), respectively (p < 0.0001). In total, 31 of the 339 patients (9.1%) failed to complete the study according to the study description. Loss to follow-up and personal conflict were the most common reasons for discontinuation. There were 30 treatment-emergent adverse events with six serious cases, assessed as unrelated to study drug, reported. Conclusion: This study further demonstrates the effectiveness and safety of olanzapine in actual clinical practice settings, in reducing the severity of psychopathological symptoms in Asian patients with schizophrenia.

Original languageEnglish
Pages (from-to)631-642
Number of pages12
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume45
Issue number12
Publication statusPublished - Dec 2007

Fingerprint

olanzapine
Brief Psychiatric Rating Scale
Schizophrenia
Outpatients
Safety
Therapeutics
Indonesia
Malaysia
Pakistan
Singapore
Thailand
Observational Studies
Labels
Psychiatry
Prospective Studies

Keywords

  • Asian patients
  • Observational study
  • Olanzapine
  • Safety
  • Schizo-phrenia

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)

Cite this

Habil, M. H., Gondoyoewono, H., Chaudhry, H. R., Samanwongthai, U., Abdul Rahman, A. H., Hashmi, I. T., ... Buenaventura, R. (2007). Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia. International Journal of Clinical Pharmacology and Therapeutics, 45(12), 631-642.

Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia. / Habil, M. Hussain; Gondoyoewono, H.; Chaudhry, H. R.; Samanwongthai, U.; Abdul Rahman, Abdul Hamid; Hashmi, I. T.; Budiman, R.; Knowles, A. G.; Buenaventura, R.

In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 45, No. 12, 12.2007, p. 631-642.

Research output: Contribution to journalArticle

Habil, MH, Gondoyoewono, H, Chaudhry, HR, Samanwongthai, U, Abdul Rahman, AH, Hashmi, IT, Budiman, R, Knowles, AG & Buenaventura, R 2007, 'Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia', International Journal of Clinical Pharmacology and Therapeutics, vol. 45, no. 12, pp. 631-642.
Habil, M. Hussain ; Gondoyoewono, H. ; Chaudhry, H. R. ; Samanwongthai, U. ; Abdul Rahman, Abdul Hamid ; Hashmi, I. T. ; Budiman, R. ; Knowles, A. G. ; Buenaventura, R. / Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia. In: International Journal of Clinical Pharmacology and Therapeutics. 2007 ; Vol. 45, No. 12. pp. 631-642.
@article{eb7ab89bd40f41c98fad30e94b144377,
title = "Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia",
abstract = "Objective: The objective of this study was to assess the effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients in an outpatient setting. Methods: This was an open-label, prospective, observational study involving 339 patients from Indonesia, Pakistan, Malaysia, Thailand, and Singapore. Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression Severity scale (CGI-S), and safety parameters were assessed. Results: 62{\%} of patients responded to olanzapine treatment, defined a priori as a reduction in BPRS of> 40{\%} from baseline. Following the 8-week treatment period, the BPRS total, BPRS positive, BPRS negative, and CGI-S scores decreased by 18.7 (95{\%} CI: 17.4, 20.2), 6.1 (5.6, 6.6), 2.9 (2.6, 3.2), and 1.5 points (median 1.0), respectively (p < 0.0001). In total, 31 of the 339 patients (9.1{\%}) failed to complete the study according to the study description. Loss to follow-up and personal conflict were the most common reasons for discontinuation. There were 30 treatment-emergent adverse events with six serious cases, assessed as unrelated to study drug, reported. Conclusion: This study further demonstrates the effectiveness and safety of olanzapine in actual clinical practice settings, in reducing the severity of psychopathological symptoms in Asian patients with schizophrenia.",
keywords = "Asian patients, Observational study, Olanzapine, Safety, Schizo-phrenia",
author = "Habil, {M. Hussain} and H. Gondoyoewono and Chaudhry, {H. R.} and U. Samanwongthai and {Abdul Rahman}, {Abdul Hamid} and Hashmi, {I. T.} and R. Budiman and Knowles, {A. G.} and R. Buenaventura",
year = "2007",
month = "12",
language = "English",
volume = "45",
pages = "631--642",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "12",

}

TY - JOUR

T1 - Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia

AU - Habil, M. Hussain

AU - Gondoyoewono, H.

AU - Chaudhry, H. R.

AU - Samanwongthai, U.

AU - Abdul Rahman, Abdul Hamid

AU - Hashmi, I. T.

AU - Budiman, R.

AU - Knowles, A. G.

AU - Buenaventura, R.

PY - 2007/12

Y1 - 2007/12

N2 - Objective: The objective of this study was to assess the effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients in an outpatient setting. Methods: This was an open-label, prospective, observational study involving 339 patients from Indonesia, Pakistan, Malaysia, Thailand, and Singapore. Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression Severity scale (CGI-S), and safety parameters were assessed. Results: 62% of patients responded to olanzapine treatment, defined a priori as a reduction in BPRS of> 40% from baseline. Following the 8-week treatment period, the BPRS total, BPRS positive, BPRS negative, and CGI-S scores decreased by 18.7 (95% CI: 17.4, 20.2), 6.1 (5.6, 6.6), 2.9 (2.6, 3.2), and 1.5 points (median 1.0), respectively (p < 0.0001). In total, 31 of the 339 patients (9.1%) failed to complete the study according to the study description. Loss to follow-up and personal conflict were the most common reasons for discontinuation. There were 30 treatment-emergent adverse events with six serious cases, assessed as unrelated to study drug, reported. Conclusion: This study further demonstrates the effectiveness and safety of olanzapine in actual clinical practice settings, in reducing the severity of psychopathological symptoms in Asian patients with schizophrenia.

AB - Objective: The objective of this study was to assess the effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients in an outpatient setting. Methods: This was an open-label, prospective, observational study involving 339 patients from Indonesia, Pakistan, Malaysia, Thailand, and Singapore. Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression Severity scale (CGI-S), and safety parameters were assessed. Results: 62% of patients responded to olanzapine treatment, defined a priori as a reduction in BPRS of> 40% from baseline. Following the 8-week treatment period, the BPRS total, BPRS positive, BPRS negative, and CGI-S scores decreased by 18.7 (95% CI: 17.4, 20.2), 6.1 (5.6, 6.6), 2.9 (2.6, 3.2), and 1.5 points (median 1.0), respectively (p < 0.0001). In total, 31 of the 339 patients (9.1%) failed to complete the study according to the study description. Loss to follow-up and personal conflict were the most common reasons for discontinuation. There were 30 treatment-emergent adverse events with six serious cases, assessed as unrelated to study drug, reported. Conclusion: This study further demonstrates the effectiveness and safety of olanzapine in actual clinical practice settings, in reducing the severity of psychopathological symptoms in Asian patients with schizophrenia.

KW - Asian patients

KW - Observational study

KW - Olanzapine

KW - Safety

KW - Schizo-phrenia

UR - http://www.scopus.com/inward/record.url?scp=37249003312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37249003312&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 631

EP - 642

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 12

ER -